Liver disease is rapidly transforming into a significant financial and healthcare challenge in India, with a new report highlighting a dramatic increase in both claims and treatment costs. According to findings from Care Health Insurance, liver disease claims have doubled over the past three years, while the associated treatment expenses have surged by nearly 100%.
Shifting Demographics and Rising Incidence
Historically, liver disease was more commonly observed among older, urban male populations. However, the Care Health Insurance report indicates a significant demographic shift. The disease is now increasingly affecting younger individuals, women, and residents in Tier 2 and Tier 3 cities. Claims among younger policyholders are rising annually by 5-10%, while Tier 2 and Tier 3 cities report a 10-15% yearly increase. Women are also an emerging segment, with claims climbing nearly 10% year-on-year.
This broadening risk pool points to a deeper, lifestyle-driven health transition, mirroring India's rising incidence of metabolic disorders. A primary driver of this trend is metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). MASLD affects an estimated 9% to 32% of Indians and often progresses silently, leading to costly interventions only at advanced stages.
Financial Burden and Insurance Implications
The dual escalation in the frequency and severity of liver disease cases carries direct implications for the health insurance sector. Insurers face challenges in underwriting, premium pricing, and managing claims ratios. For households, the financial burden is becoming substantially heavier. Manish Dodeja, COO of Care Health Insurance, emphasized this shift:
"Liver diseases are no longer confined to a narrow risk pool. Cases are rising sharply, younger populations are getting impacted, and the financial burden on households is becoming significantly heavier. This is not just a clinical issue—it is increasingly an economic one."
With treatment expenses, particularly for advanced cases requiring hospitalization or transplants, rising sharply, a minimum health cover of ₹15 lakh is now considered a baseline. This trend is pushing insurers to design higher-ticket policies and more comprehensive coverage options to meet evolving demand.
Long-Term Outlook and Global Trends
The long-term projections for liver disease are equally concerning. Clinical data suggests a rising incidence even among children, especially those with obesity and other metabolic risk factors. Projections indicate that over 1.19 crore Indian children could be affected by 2040, signaling a sustained pipeline for future healthcare demand.
Globally, the trend is even more pronounced. A Lancet study estimates that MASLD cases could reach 1.8 billion by 2050, fueled by population growth and lifestyle changes. In India, rapid urbanization, dietary shifts, and sedentary behavior are accelerating this trajectory.
For investors, this evolving landscape presents a complex signal. While the rising disease burden translates into increased demand for healthcare services, diagnostics, pharmaceuticals, and insurance products, it also raises critical questions about affordability, claims sustainability, and long-term cost inflation within the broader healthcare ecosystem.